| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_55c3f9b0a08cdacab568bf142f8ef80a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b5d1de0cb099ee72980dadb3b90d66d8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_300903ddd488223fe9c98b2f1f2cd03c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fddb3fc85dc2bbc6fd8e8b348f00fcd7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e253661ef0079638605fe5e327287a8f |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70578
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2006-08-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2014-08-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_02f3e5e7bfe325f4bcbb48b20543ab0f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b1d7cbf4b3d09ef67a5ebd1f19b8457d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_24bd6c06c0ea8e9972fae52cafb2b99e |
| publicationDate |
2014-08-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-8808696-B2 |
| titleOfInvention |
Methods for the treatment and prevention of abnormal cell proliferation using TACI-fusion molecules |
| abstract |
The present invention provides methods and compositions for treatment of hyperproliferative disorders and cancers, including multiple myeloma and Waldenström's macroglobulinemia, comprising administering to a patient in need of the treatment a TACI-Ig fusion molecule in amount sufficient to suppress proliferation-inducing functions of BlyS and APRIL. |
| priorityDate |
2005-08-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |